A New VISTA on combination therapy for negative checkpoint regulator blockade

Area of Science:

• Immunology
• Cancer Biology
• Immunotherapy

Background:

• Negative checkpoint regulators (NCRs) are crucial for maintaining self-tolerance and preventing autoimmune diseases by restraining T cell activity.
• Malignancies often hijack NCR pathways to facilitate immune evasion, leading to tumor progression and clinical cancer development.
• Recent clinical trials with blocking antibodies against NCRs have significantly advanced cancer immunotherapy.

Approach:

• This review synthesizes current knowledge on established NCR blockade strategies.
• It explores the potential of combining existing therapies with anti-VISTA antibody treatments.
• The focus is on targeting multiple, non-redundant NCR pathways for enhanced anti-cancer immunity.

Key Points:

• NCRs present a critical barrier to effective anti-tumor T cell responses.
• Combining therapies that block distinct NCRs can overcome redundant immune escape mechanisms.
• Anti-VISTA antibody offers a promising avenue for combination immunotherapy by targeting a key NCR.

Conclusions:

• Targeting NCRs is a validated approach in cancer immunotherapy.
• Combination strategies, including anti-VISTA, hold significant potential for overcoming tumor immune evasion.
• Further research into multi-pathway NCR blockade is warranted to improve clinical outcomes.